XSTOINIT
Market cap32mUSD
Dec 20, Last price
6.80SEK
1D
-1.45%
1Q
-6.85%
IPO
47.03%
Name
Initiator Pharma A/S
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
15.15%
Rev. gr., 5y
%
Revenues
0k
Net income
-23k
L-99.94%
CFO
-18m
L-46.03%
Earnings
Feb 28, 2025
Profile
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectile dysfunction; IPED2015 to treat patients suffering from organic erectile dysfunction; and IPTN2021 for targeting an orphan drug indication in severe neuropathic pain. The company's pre-clinical stage candidates include IPNP2015 for the treatment of chronic pain; and IPDP2015 for depression. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.
Valuation
Title DKK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 39 | 65 | 33 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (39) | (65) | (33) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 5 | (5,677) | (3,180) | |||||
Tax Rate | ||||||||
NOPAT | (44) | 5,612 | 3,147 | |||||
Net income | (23) -99.94% | (38,455) 82.56% | (21,064) 142.20% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 12 | 37,484 | 41,648 | |||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | 15,437 | 12,577 | 13,290 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | (8,899) | (26,335) | (20,856) | |||||
| Cash flow | ||||||||
Cash from operating activities | (17,648) | (32,701) | (34,097) | |||||
CAPEX | ||||||||
Cash from investing activities | (17) | |||||||
Cash from financing activities | 2,871 | 37,484 | 54,938 | |||||
FCF | (2,290) | 5,612 | 3,147 | |||||
| Balance | ||||||||
Cash | 24,336 | 38,912 | 34,146 | |||||
Long term investments | ||||||||
Excess cash | 24,336 | 38,912 | 34,146 | |||||
Stockholders' equity | 11,162 | 34,023 | 34,994 | |||||
Invested Capital | 15,437 | 12,577 | 14,138 | |||||
ROIC | 42.02% | 41.29% | ||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 52,419 | 53,226 | 39,685 | |||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | (39) | (65) | (22) | |||||
EV/EBITDA | ||||||||
Interest | 2,392 | 1,172 | ||||||
Interest/NOPBT | ||||||||